Skip to main content
Top
Published in: Obesity Surgery 4/2010

01-04-2010 | Clinical Research

Chronic Increase of Bone Turnover Markers After Biliopancreatic Diversion is Related to Secondary Hyperparathyroidism and Weight Loss. Relation with Bone Mineral Density

Authors: José Antonio Balsa, José I. Botella-Carretero, Roberto Peromingo, Carmen Caballero, Teresa Muñoz-Malo, Juan J. Villafruela, Francisco Arrieta, Isabel Zamarrón, Clotilde Vázquez

Published in: Obesity Surgery | Issue 4/2010

Login to get access

Abstract

Background

Biliopancreatic diversion (BPD) is the most effective bariatric procedure. Around 70% of these patients have secondary hyperparathyroidism (SH) in the long term as a consequence of calcium and vitamin D malabsorption. This work was aimed to study the influence of SH on bone turnover and its relationship with bone mineral density (BMD).

Methods

Bone turnover markers were determined in 63 BPD patients and 34 morbidly obese controls. In the BPD group, we also studied the influence of age, loss of weight, common channel length, PTH, vitamin D, and serum calcium on bone turnover as well as its relation with BMD.

Results

BPD patients showed significantly higher PTH, osteocalcin, and β-CTx levels than controls. In the multivariate regression analysis, only PTH (β = 0.42; P = 0.0002), menopausal status (β = 0.31; P = 0.007) and the percentage of lost BMI (β = −0.24; P = 0.03) significantly predicted the osteocalcin level (R 2 = 0.33; F = 9.56; P < 0.0001). Similarly, only PTH (β = 0.39; P = 0.0005), menopausal status (β = 0.37; P = 0.001) and the percentage of lost BMI (β = −0.23; P = 0.04) significantly predicted the β-CTx level (R 2 = 0.33; F = 9.82; P < 0.0001). Osteocalcin and β-CTx levels correlated negatively with BMD at lumbar spine (r = −0.38, P = 0.002 and r = −0.30, P = 0.02, respectively).

Conclusions

Chronic SH and the loss of weight determine a high rate of bone turnover that is associated with decreasing BMD in BPD patients.
Literature
1.
go back to reference Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936–46.CrossRefPubMed Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936–46.CrossRefPubMed
2.
go back to reference Balsa JA, Botella-Carretero JI, Peromingo R, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008;31:845–50.PubMed Balsa JA, Botella-Carretero JI, Peromingo R, et al. Role of calcium malabsorption in the development of secondary hyperparathyroidism after biliopancreatic diversion. J Endocrinol Invest. 2008;31:845–50.PubMed
3.
go back to reference Newbury L, Dolan K, Hatzifotis M, et al. Depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg. 2003;13:893–5.CrossRefPubMed Newbury L, Dolan K, Hatzifotis M, et al. Depletion and elevated parathyroid hormone following biliopancreatic diversion. Obes Surg. 2003;13:893–5.CrossRefPubMed
4.
go back to reference Pugnale N, Giusti V, Suter M, et al. Bone metabolism and risk of secondary hyperparathyroidism 12 months after gastric banding in obese pre-menopausal women. Int J Obes Relat Metab Disord. 2003;27:110–6.CrossRefPubMed Pugnale N, Giusti V, Suter M, et al. Bone metabolism and risk of secondary hyperparathyroidism 12 months after gastric banding in obese pre-menopausal women. Int J Obes Relat Metab Disord. 2003;27:110–6.CrossRefPubMed
5.
go back to reference Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg. 2003;13:383–8.CrossRefPubMed Guney E, Kisakol G, Ozgen G, et al. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. Obes Surg. 2003;13:383–8.CrossRefPubMed
6.
go back to reference Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061–5.CrossRefPubMed Coates PS, Fernstrom JD, Fernstrom MH, et al. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061–5.CrossRefPubMed
8.
go back to reference Gamero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int. 1996;52:S2–9. Gamero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int. 1996;52:S2–9.
9.
go back to reference Taylor AK, Lueken SA, Libanati C, et al. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994;20:589–607.PubMed Taylor AK, Lueken SA, Libanati C, et al. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994;20:589–607.PubMed
10.
go back to reference De Leo V, Ditto A, la Marca A, et al. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int. 2000;66:263–7.CrossRefPubMed De Leo V, Ditto A, la Marca A, et al. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int. 2000;66:263–7.CrossRefPubMed
11.
go back to reference Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefPubMed Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefPubMed
12.
go back to reference Duda RJ Jr, O’Brien JF, Katzmann JA, et al. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab. 1988;66:951–7.CrossRefPubMed Duda RJ Jr, O’Brien JF, Katzmann JA, et al. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab. 1988;66:951–7.CrossRefPubMed
13.
go back to reference Deftos LJ, Parthemore JG, Price PA. Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int. 1982;34:121–4.CrossRefPubMed Deftos LJ, Parthemore JG, Price PA. Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int. 1982;34:121–4.CrossRefPubMed
14.
go back to reference Brown JP, Delmas PD, Malaval L, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091–3.CrossRefPubMed Brown JP, Delmas PD, Malaval L, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091–3.CrossRefPubMed
15.
go back to reference Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem. 2001;47:1410–4.PubMed Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem. 2001;47:1410–4.PubMed
16.
go back to reference Fledelius C, Johnsen AH, Cloos PA, et al. Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem. 1997;272:9755–63.CrossRefPubMed Fledelius C, Johnsen AH, Cloos PA, et al. Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem. 1997;272:9755–63.CrossRefPubMed
17.
go back to reference Okabe R, Inaba1 M, Nakatsuka K, et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab. 2004;22:127–31.CrossRefPubMed Okabe R, Inaba1 M, Nakatsuka K, et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab. 2004;22:127–31.CrossRefPubMed
18.
go back to reference Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998;44:2281–9.PubMed Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998;44:2281–9.PubMed
19.
go back to reference Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg. 2004;8:48–55.CrossRefPubMed Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg. 2004;8:48–55.CrossRefPubMed
20.
go back to reference Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93:3735–40.CrossRefPubMed Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93:3735–40.CrossRefPubMed
21.
go back to reference Moreiro J, Ruiz O, Perez G, et al. Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes Surg. 2007;17:348–54.CrossRefPubMed Moreiro J, Ruiz O, Perez G, et al. Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion. Obes Surg. 2007;17:348–54.CrossRefPubMed
22.
go back to reference Chapin BL, LeMar HJJ, Knodel DH, et al. Secondary hyperparathyroidism following biliopancreatic diversion. Arch Surg. 1996;131:1048–52.PubMed Chapin BL, LeMar HJJ, Knodel DH, et al. Secondary hyperparathyroidism following biliopancreatic diversion. Arch Surg. 1996;131:1048–52.PubMed
23.
go back to reference Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr. 2005;81:1232S–9S.PubMed Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr. 2005;81:1232S–9S.PubMed
24.
go back to reference Rosen C, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904–10.CrossRefPubMed Rosen C, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904–10.CrossRefPubMed
25.
go back to reference Dresner-Pollak R, Parker RA, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59:328–33.CrossRefPubMed Dresner-Pollak R, Parker RA, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59:328–33.CrossRefPubMed
26.
go back to reference Reeve J, Pearson J, Mitchell A, et al. Evolution of spinal bone loss and biochemical markers of bone remodelling after menopause in normal women. Calcif Tissue Int. 1995;57:105–10.CrossRefPubMed Reeve J, Pearson J, Mitchell A, et al. Evolution of spinal bone loss and biochemical markers of bone remodelling after menopause in normal women. Calcif Tissue Int. 1995;57:105–10.CrossRefPubMed
27.
go back to reference Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 1996;13:297–302.CrossRef Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 1996;13:297–302.CrossRef
28.
go back to reference Riggs BL, Melton LJ III, O’Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18:S197–201.CrossRef Riggs BL, Melton LJ III, O’Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18:S197–201.CrossRef
29.
go back to reference Marceau P, Biron S, Lebel S, et al. Does bone change after biliopancreatic diversion? J Gastrointest Surg. 2002;6:690–8.CrossRefPubMed Marceau P, Biron S, Lebel S, et al. Does bone change after biliopancreatic diversion? J Gastrointest Surg. 2002;6:690–8.CrossRefPubMed
Metadata
Title
Chronic Increase of Bone Turnover Markers After Biliopancreatic Diversion is Related to Secondary Hyperparathyroidism and Weight Loss. Relation with Bone Mineral Density
Authors
José Antonio Balsa
José I. Botella-Carretero
Roberto Peromingo
Carmen Caballero
Teresa Muñoz-Malo
Juan J. Villafruela
Francisco Arrieta
Isabel Zamarrón
Clotilde Vázquez
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 4/2010
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-009-0028-z

Other articles of this Issue 4/2010

Obesity Surgery 4/2010 Go to the issue